Three diagnostic mistakes account for 75% of malpractice claims

Just three categories of diagnostic errors account for roughly 75% of all serious misdiagnosis-related harms to patients, according to a new study published in Diagnosis. Diagnostic errors are a big problem in the U.S., though estimates vary widely, from 40,000 to 4 million patients affected annually.

The three categories include vascular events, infections and cancers. In addition, about half of the serious harms from diagnostic error were attributable to one of 15 disease states. The results were true across a variety of settings. Half of the high-severity harms caused and half caused serious, permanent disability.

“These results suggest considerable progress could be made toward reducing overall serious misdiagnosis-related harms by improving diagnostic decision-making for a relatively small number of high-risk conditions in just a few clinical settings,” lead author David Newman-Toker, MD, of the Johns Hopkins School of Medicine, and colleagues wrote.

According to researchers, diagnostic errors are the “most common, most catastrophic and most costly of serious medical errors” in malpractice cases.

The study examined 11,592 diagnostic error cases over a 10-year window, with the most frequent disease in each category reported as stroke, sepsis and lung cancer. In 85.7% of cases, the causes of diagnostic error were clinical judgement factors.

“This result accords with prior work indicating that the vast majority of diagnostic process failures happen in bedside assessment and clinical reasoning … and points to a need for solutions that support better bedside clinical decision-making,” Newman-Toker et al. wrote.

Some of these solutions include device-based decision support or automated image interpretation, as well as improved diagnostic education. Higher investments in preventing misdiagnosis could also be beneficial.

“Our current annual federal investment to fix diagnostic errors is less than what we spend each year researching smallpox, a disease eradicated in the U.S. over half a century ago," Newman-Toker said in a statement. "If we devoted appropriate resources to tackling misdiagnosis of the 'big three' diseases we identified, we could potentially save half of the people who die or are permanently disabled from diagnostic errors."

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.